Before a formula can be great, the science behind it has to be right. Two bodies of theoretical work — both deeply associated with Dr. Russo — form the foundation of how CReDO approaches every formulation and every drug development engagement.
The term "entourage effect" was coined by renowned researchers Ben Shabat and Raphael Mechoulam in 1998, but it was Dr. Russo who built the scientific case for it with respect to cannabis and brought it into mainstream pharmacological thinking — most influentially through his landmark paper Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects, published in the British Journal of Pharmacology in 2011.
The concept is this: cannabis is not a single-molecule medicine. The plant contains hundreds of compounds — cannabinoids, terpenes, flavonoids — that work together in ways that produce outcomes no single isolated compound can replicate. They act through multiple mechanisms, across multiple systems in the body, simultaneously. The result is superior therapeutic effect with fewer side effects and, in some cases, side benefits. The whole, in other words, is genuinely greater than the sum of its parts.
This is not a marketing concept. It is a pharmacological reality with a growing body of peer-reviewed evidence behind it — and it is the reason CReDO develops complex, whole-plant, indication-optimized formulas rather than single-molecule isolates. Every licensing deal, every drug program, every formulation CReDO has built reflects this principle.
Links to Journal Articles for more in depth reading:
In 2001, Dr. Russo proposed a theory that would prove to be one of the most consequential ideas in cannabis medicine: that the endocannabinoid system — the body's own system for maintaining physiological balance — can become deficient, and that this deficiency may underlie a range of treatment-resistant conditions including migraine, fibromyalgia, and irritable bowel syndrome.
The theory, known as Clinical Endocannabinoid Deficiency, or CED, reframes how we think about cannabis-based medicine. If the endocannabinoid system can be deficient, then cannabis-based medicines aren't merely providing symptomatic relief — they are addressing an underlying physiological deficit. That distinction matters enormously for how indications are framed, how clinical trials are designed, and how cannabis-based drugs are positioned within the broader pharmacological landscape.
Twenty years of subsequent research has continued to support the theory. Dr. Russo revisited and strengthened the case in Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes, published in Cannabis and Cannabinoid Research.
For companies developing cannabis-based drugs, CECD is not just an interesting theory. It is a clinical argument — one that can inform indication selection, patient population targeting, and the scientific narrative a drug program needs to carry into trials and regulatory review.
Links to Journal Articles for more in depth reading:
For years, patients using CBG-predominant cannabis preparations reported meaningful relief — particularly for anxiety. The problem was that the clinical science hadn't caught up to the patient experience. CReDO helped change that.
The research arc began with a systematic patient survey, published in Cannabis and Cannabinoid Research, examining the perceived medical effects, adverse events, and withdrawal symptoms among patients using CBG-predominant cannabis preparations. The findings were striking: the majority of CBG users reported using it to manage anxiety and 29 other symptoms and conditions, with most asserting it was more effective than conventional anxiety medications. That survey established the patient-reported case — and created the scientific rationale for a controlled trial.
In 2024, the team headed by Carrie Cuttler, PhD published the results of the first human clinical trial on CBG's effects on anxiety and stress — a double-blind, placebo-controlled, crossover field trial — in Scientific Reports, a journal that is part of the Nature publishing portfolio. The results confirmed what patients had been reporting: 20mg of hemp-derived CBG significantly reduced anxiety and stress compared to placebo, at multiple time points after ingestion. CBG also enhanced verbal memory relative to placebo. Critically, there was no evidence of intoxication, cognitive impairment, or significant side effects.
The study's conclusion: CBG may represent a novel, non-intoxicating option for reducing stress and anxiety in adults — and the science now exists to back that up.
CReDO Science is listed as an institutional affiliation on this study. This is what it looks like when consulting expertise and original research operate as one.
Cannabinoid Hyperemesis Syndrome — CHS — is one of the most misdiagnosed conditions in cannabis medicine. For years it was misattributed or simply missed by clinicians who had never been trained to recognize it. Dr. Ethan Russo was among the first to take it seriously as a distinct clinical entity — and among the first to hypothesize that its origins were genetic.
That hypothesis turned out to be correct.
CReDO led the first genomic study of CHS — a peer-reviewed survey and genomic investigation published in Cannabis and Cannabinoid Research. The study identified five genes with statistically significant associations with CHS risk, providing the first scientific framework for understanding why some cannabis users develop this debilitating syndrome and others do not. The implications are significant: for the first time, it became possible to think about CHS not just as something to treat after the fact, but as something that can be anticipated — and potentially screened for — before it occurs.
That research gave rise to something practical: a DNA-based CHS susceptibility test, available now. The test identifies genetic markers associated with elevated CHS risk, giving patients, clinicians, and cannabis users actionable information before symptoms develop.
If you or someone you care for uses cannabis and has experienced unexplained cyclical nausea and vomiting, or if you simply want to understand your genetic risk profile before beginning cannabis use, this test was built for you.
Our dedicated CHS resource site — what-is-chs.com — brings together everything currently known about Cannabinoid Hyperemesis Syndrome in one place: videos, FAQs, patient stories, and the latest science. It is designed for patients trying to understand what is happening to them, caregivers trying to help, and clinicians who need a reliable reference.
These research programs span two decades and multiple disciplines — from foundational pharmacological theory to genomic investigation to the first placebo-controlled human trial on a previously understudied cannabinoid. They look different on the surface. But they come from exactly the same place: a conviction that cannabis medicine deserves the same rigorous scientific attention as any other area of pharmacology, and that patients deserve to benefit from that science as directly and quickly as possible.
The Entourage Effect explains why whole-plant formulas work better. CED explains why some patients need them more than others. The CBG trial proves that understudied cannabinoids can be brought into evidence-based medicine. The CHS genomic study shows that cannabis can also cause harm in specific populations — and that understanding that harm is just as important as understanding the benefits.
Together, they are a body of work that reflects what CReDO is: a research-led organization that builds its commercial practice on science it has helped create.
For Dr. Russo's complete publication library:
